【BIOHLDG 0179 交流专区】

icy97

BIOALPHA HOLDINGS BERHAD

Particulars of substantial Securities Holder

Name	MR HON TIAN KOK@WILLIAM
Nationality/Country of incorporation	Malaysia
Descriptions (Class)	Ordinary shares

Details of changes

No	Date of change	No of securities	Type of Transaction	Nature of Interest
1	14 Apr 2020	15,838,900	Disposed	Direct Interest
	Name of registered holder	Hon Tian Kok @ William
	Address of registered holder	No 31, Jln SL5/1, Bandar Sungai Long, 43000 Kajang, Selangor Darul Ehsan
	Description of "Others" Type of Transaction
2	14 Apr 2020	2,761,100	Disposed	Direct Interest
	Name of registered holder	Hon Tian Kok @ William
	Address of registered holder	No 31, Jln SL5/1, Bandar Sungai Long, 43000 Kajang, Selangor Darul Ehsan
	Description of "Others" Type of Transaction
3	15 Apr 2020	13,500,000	Disposed	Direct Interest
	Name of registered holder	Hon Tian Kok @ William
	Address of registered holder	No 31, Jln SL5/1, Bandar Sungai Long, 43000 Kajang, Selangor Darul Ehsan
	Description of "Others" Type of Transaction
4	15 Apr 2020	5,500,000	Disposed	Direct Interest
	Name of registered holder	Hon Tian Kok @ William
	Address of registered holder	No 31, Jln SL5/1, Bandar Sungai Long, 43000 Kajang, Selangor Darul Ehsan
	Description of "Others" Type of Transaction
5	15 Apr 2020	400,000	Disposed	Direct Interest
	Name of registered holder	Hon Tian Kok @ William
	Address of registered holder	No 31, Jln SL5/1, Bandar Sungai Long, 43000 Kajang, Selangor Darul Ehsan
	Description of "Others" Type of Transaction
6	16 Apr 2020	15,400	Disposed	Direct Interest
	Name of registered holder	Hon Tian Kok @ William
	Address of registered holder	No 31, Jln SL5/1, Bandar Sungai Long, 43000 Kajang, Selangor Darul Ehsan
	Description of "Others" Type of Transaction
7	17 Apr 2020	3,616,900	Disposed	Direct Interest
	Name of registered holder	Hon Tian Kok @ William
	Address of registered holder	No 31, Jln SL5/1, Bandar Sungai Long, 43000 Kajang, Selangor Darul Ehsan
	Description of "Others" Type of Transaction
8	17 Apr 2020	1,500,000	Disposed	Direct Interest
	Name of registered holder	Hon Tian Kok @ William
	Address of registered holder	No 31, Jln SL5/1, Bandar Sungai Long, 43000 Kajang, Selangor Darul Ehsan
	Description of "Others" Type of Transaction

Circumstances by reason of which change has occurred	Disposal of 43,132,300 ordinary shares via open market.
Nature of interest	Direct Interest
Direct (units)	56,867,700
Direct (%)	6.64
Indirect/deemed interest (units)	0
Indirect/deemed interest (%)	0
Total no of securities after change	56,867,700
Date of notice	17 Apr 2020
Date notice received by Listed Issuer	17 Apr 2020

icy97

BIOALPHA HOLDINGS BERHAD

1. Details of Corporate Proposal
Involve issuance of new type/class of securities ?	No
Types of corporate proposal	ESOS
Details of corporate proposal	Exercise of ESOS
No. of shares issued under this corporate proposal	50,000,000
Issue price per share ($$)	Malaysian Ringgit (MYR)   0.1050
Par Value($$) (if applicable)	Malaysian Ringgit (MYR)   0.000
Latest issued share capital after the above corporate proposal in the following
Units	910,209,032
Issued Share Capital ($$)	Malaysian Ringgit (MYR) 105,013,799.000
Listing Date	24 Apr 2020

icy97

BIOALPHA HOLDINGS BERHAD

Particulars of substantial Securities Holder

Name	MR HON TIAN KOK @ WILLIAM
Nationality/Country of incorporation	Malaysia
Descriptions (Class)	Ordinary Shares

Details of changes

No	Date of change	No of securities	Type of Transaction	Nature of Interest
1	22 Apr 2020	50,000,000	Others	Direct Interest
	Name of registered holder	HON TIAN KOK @ WILLAM
	Address of registered holder	No 31, Jln SL5/1, Bandar Sungai Long, 43000 Kajang, Selangor Darul Ehsan
	Description of "Others" Type of Transaction	Exercise of Options

Circumstances by reason of which change has occurred	Exercise of Options
Nature of interest	Direct Interest
Direct (units)	106,867,700
Direct (%)	11.741
Indirect/deemed interest (units)	0
Indirect/deemed interest (%)	0
Total no of securities after change	106,867,700
Date of notice	23 Apr 2020
Date notice received by Listed Issuer	23 Apr 2020

pts2222

Type	Announcement
Subject	OTHERS
Description	BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR "THE COMPANY") - Partnership Agreement and Supply Contract Agreement
The Board of Directors of Bioalpha is pleased to announce that Bioalpha (HK) Limited (“Bioalpha HK”), a wholly-owned subsidiary of the Company had on 22 July 2020 entered into a Partnership Agreement (“PA”) with Guizhou Yuhexin Trading Ltd (“GYHX”) and Hainan Shifengfu Co. Ltd (“HSFF”) and a Supply Contract Agreement (“SCA”) with GYHX for the purpose of establishing a business partnership in People’s Republic of China (“China”) that involve health food and nutritional meals , technology transfer, research and development, manufacturing, and trading. Further details of the PA & SCA are set out in the ensuing sections. The details are set out in the attachment below. This announcement is dated 22 July 2020.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3070720

Attachments BHB-partnership and supply contract agmt (clean).pdf

https://www.theedgemarkets.com/a ... 3%E4%B8%AD%E5%9B%BD

pts2222

（吉隆坡23日讯）马股回吐部分涨幅，而在中国获得21亿令吉合约的科鼎（Bioalpha Holdings Bhd），升至2018年11月以来的最高水平。

截至10时，富时隆综指扬7.40点，报1594.38点，盘中曾升至1598.12点。

市场广度正面，上升股438只、下跌股289只，404只无起落。成交量有34亿2000万股，值16亿4000万令吉。

主要上升股包括Top Glove Corp Bhd、Pharmaniaga Holdings Bhd、Duopharma Biotech Bhd、Supermax Corp Bhd、Malaysian Pacific Industries Bhd、Careplus Group Bhd、Apex Healthcare Bhd和Bursa Malaysia Bhd。

热门股有Bioalpha、Eduspec Holdings Bhd、PDZ Holdings Bhd、XOX Bhd、Priceworth International Bhd、DGB Asia Bhd及Careplus。

下跌股则有Nestle (M) Bhd、Dutch Lady Milk Industries Bhd、Malaysia Airports Holdings Bhd、Sunway Construction Group Bhd和JF Technology Bhd。

科鼎上涨6仙，至24仙。

彭博社报道，亚洲股市周四小幅开低，因投资者对美国新刺激计划出台时机存疑，以及对中美紧张关系升级担忧。美元继续小幅走低，接近3月以来的最低。

丰隆投资银行研究指出，在担忧第二波感染、中美地缘政治紧张加剧，以及挥之不去的政治不确定因素，国内经济和企业盈利面临下行风险。

“此外，顶级手套及贺特佳（Hartalega Holdings Bhd）昨日合共占综指市值的约12%，这两只股的股价波动将继续影响综指的短期表现。”

“我们预计，市场将继续健康盘整，中和超买的技术动能，推动未来更持久的上升趋势。

该研究机构说，主要阻力水平是1600、1617和1633点，而支撑位落在1563、1546和1525点。

Tony-Pua

（吉隆坡23日讯）在宣布获得 21亿令吉的保健食品合约后， 科鼎（BIOHLDG，0179，创业板消费）股价今日一度狂涨超过一倍至39.5仙，连带其公司凭单科鼎-WA也跟着大涨4倍至35仙！



科鼎以20.5仙开市；闭市时，该股报31仙，起13仙或72.2%，成交量高达21亿9936万3400股，为马马股最热门股项。

至于科鼎-WA今早以8.5仙开市；闭市时，该股扬18.5仙或大涨近3倍至25.5仙，并列马股30大上升股榜，成交量6亿9350万8200股。

科鼎获得保健食品合约后，股价涨翻天！
科鼎获得保健食品合约后，股价涨翻天！
今日闭市时，科鼎与科鼎-WA分别称霸十大热门股榜的冠军及亚军位置。两者成交量合计近29亿股，占马股全日成交量121亿股，将近四分之一。

科鼎向马证交所报备，旗下香港独资子公司Bioalpha有限公司与中国2家公司，即Guizhou Yuhexin Trading有限公司，以及Hainan Shifengfu有限公司达成合作协议，为中国公共和私营领域供应保健食品和营养膳食原料。

icy97

Type	Announcement
Subject	NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) FUND RAISING
Description	BIOALPHA HOLDINGS BHD ("BIOALPHA" OR THE "COMPANY")PROPOSED PRIVATE PLACEMENT OF NEW ORDINARY SHARES IN BIOALPHA, REPRESENTING UP TO 10% OF THE ENLARGED NUMBER OF ISSUED SHARES OF BIOALPHA (EXCLUDING TREASURY SHARES) ("PROPOSED PRIVATE PLACEMENT")
On behalf of the Board of Directors of Bioalpha (“Board”), TA Securities Holdings Berhad (“TA Securities”) wishes to announce that the Company proposes to undertake the Proposed Private Placement. Please refer to the attachment below for further details on the announcement. This announcement is dated 4 June 2020.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3056227

Attachments Bioalpha - Announcement (Proposed Private Placement).pdf

icy97

Type	Announcement
Subject	NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) FUND RAISING
Description	BIOALPHA HOLDINGS BHD ("BIOALPHA" OR THE "COMPANY")PROPOSED PRIVATE PLACEMENT OF NEW ORDINARY SHARES IN BIOALPHA, REPRESENTING UP TO 10% OF THE ENLARGED NUMBER OF ISSUED SHARES OF BIOALPHA (EXCLUDING TREASURY SHARES) ("PROPOSED PRIVATE PLACEMENT")
We refer to the announcements made on 4 June 2020 and 5 June 2020 in relation to the Proposed Private Placement (“Announcements”). Unless otherwise defined, the definitions set out in the Announcements shall apply herein. On behalf of Bioalpha, TA Securities wishes to provide additional information in relation to the utilisation of proceeds from the Proposed Private Placement. Further details are set out in the attachment below. This announcement is dated 17 June 2020.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3059318

Attachments Announcement (Additional information).pdf

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Mar 2020

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Mar 2020	31 Mar 2019	31 Mar 2020	31 Mar 2019
		$$'000	$$'000	$$'000	$$'000

1	Revenue	6,532	12,482	6,532	12,482
2	Profit/(loss) before tax	-5,305	1,266	-5,305	1,266
3	Profit/(loss) for the period	-5,689	944	-5,689	944
4	Profit/(loss) attributable to ordinary equity holders of the parent	-5,503	858	-5,503	858
5	Basic earnings/(loss) per share (Subunit)	-0.64	0.10	0.64	0.10
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1850		0.1922

icy97

icy97 发表于 28-8-2019 06:49 AM
http://www.bursamalaysia.com/market/listed-companies/company-announcements/6265321

Type	Announcement
Subject	OTHERS
Description	BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR THE "COMPANY")PROPOSED TRANSFER OF LISTING
We refer to the announcements dated 27 August 2019 and 30 August 2019 in relation to the Proposed Transfer of Listing. Unless otherwise defined, capitalised terms used in this announcement have the same meanings as those given to them in the previous announcements. On behalf of the Board, Hong Leong Investment Bank Berhad wishes to announce that after due and careful consideration, the Board has resolved to abort the Proposed Transfer of Listing. Such decision was made after taking into consideration, amongst others, the adverse impact of the coronavirus disease 2019 (“Covid-19”) and movement control order announced by the Government of Malaysia, on the financial performance of Bioalpha and its subsidiaries (“Group”) in the financial year ending 31 December 2020. With the current uncertainty surrounding the recovery of the global and local economy due to Covid-19, the performance of the Group for the financial year ending 31 December 2020 will remain challenging. Hence, the Board is of the view that the prevailing economic environment is not the best time for the Company to continue with the Proposed Transfer of Listing. This announcement is dated 25 June 2020.

icy97

BIOALPHA HOLDINGS BERHAD

1. Details of Corporate Proposal
Involve issuance of new type/class of securities ?	No
Types of corporate proposal	Private Placement
Details of corporate proposal	PRIVATE PLACEMENT OF NEW ORDINARY SHARES IN BIOALPHA HOLDINGS BERHAD ("BIOALPHA"), REPRESENTING UP TO 10% OF THE ENLARGED NUMBER OF ISSUED SHARES IN BIOALPHA (EXCLUDING TREASURY SHARES) ("PRIVATE PLACEMENT")
No. of shares issued under this corporate proposal	44,309,700
Issue price per share ($$)	Malaysian Ringgit (MYR)   0.1050
Par Value($$) (if applicable)	Malaysian Ringgit (MYR)   0.000
Latest issued share capital after the above corporate proposal in the following
Units	991,168,732
Issued Share Capital ($$)	Malaysian Ringgit (MYR) 113,514,566.920
Listing Date	09 Jul 2020

icy97

BIOALPHA HOLDINGS BERHAD

1. Details of Corporate Proposal
Involve issuance of new type/class of securities ?	No
Types of corporate proposal	Private Placement
Details of corporate proposal	PRIVATE PLACEMENT OF NEW ORDINARY SHARES IN BIOALPHA HOLDINGS BERHAD ("BIOALPHA"), REPRESENTING UP TO 10% OF THE ENLARGED NUMBER OF ISSUED SHARES IN BIOALPHA (EXCLUDING TREASURY SHARES) ("PRIVATE PLACEMENT")
No. of shares issued under this corporate proposal	50,000,000
Issue price per share ($$)	Malaysian Ringgit (MYR)   0.1050
Par Value($$) (if applicable)	Malaysian Ringgit (MYR)   0.000
Latest issued share capital after the above corporate proposal in the following
Units	1,041,168,732
Issued Share Capital ($$)	Malaysian Ringgit (MYR) 118,764,566.920
Listing Date	17 Jul 2020

icy97

Type	Announcement
Subject	OTHERS
Description	BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR "THE COMPANY") - Partnership Agreement and Supply Contract Agreement
Unless otherwise stated, all abbreviations used herein shall have the same meaning as those mentioned in the announcement dated 22 July 2020 in relation to the Partnership Agreement and Supply Contract Agreement (“Announcement”). The Board of Directors of Bioalpha Holdings Berhad (“Bioalpha” or “the Company) wishes to inform that the Company has received Bursa Malaysia Securities Berhad’s request dated 23 July 2020 for additional information in relation to the Company’s announcement made on 22 July 2020. The additional information are as follows: 1. Whether the Agreements is subject to renewal, and if yes, the details of such renewal. Both Agreements are subject to annual renewal to be mutually agreed upon respective parties satisfying performance. 2. The basis and justification in arriving the value of the health food and nutritional meals to be supplied of approximately RMB700,000,000 per year (equivalent to RM426,700,000). The supply contract value of RMB700,000,000 was offered by GYHX based on their requirements to meet the market consumption (public and private sector) based on its high population and health conscious awareness of the health food and nutritional meals. 3. The commencement date of the Agreements. The commencement date of the Agreements are expected to commence in September 2020. 4.The name of directors and shareholders of Guizhou Yuhexin Trading Ltd. (“GYHX”) and Hainan Shifengfu Co. Ltd (“HSFF”), and their direct and indirect shareholdings therein. The name of directors and shareholders of GYHX and HSFF and their direct and indirect shareholdings are follows: GYHX HSFF Directors/Shareholders Wei Xuan Xuan Xu Zhen Jie Shareholdings 100% owned 100% owned This announcement is dated 24 July 2020.

icy97

Notice of Interest Sub. S-hldr (Section 137 of CA 2016)

BIOALPHA HOLDINGS BERHAD

Particulars of Substantial Securities Holder

Name	MR OOI KENG THYE
Nationality/Country of incorporation	Malaysia
Descriptions (Class)	Ordinary Shares
Name of registered holder	Maybank Nominess (Tempatan) Sdn Bhd Pledge Securities for Ooi Keng Thye

Date interest acquired & no of securities acquired
Date interest acquired	25 Aug 2020
No of securities	5,380,000
Circumstances by reason of which Securities Holder has interest	Open market transaction
Nature of interest	Direct Interest
Total no of securities after change
Direct (units)	58,143,600
Direct (%)	5.508
Indirect/deemed interest (units)	0
Indirect/deemed interest (%)	0
Date of notice	26 Aug 2020
Date notice received by Listed Issuer	26 Aug 2020

icy97

Type	Announcement
Subject	OTHERS
Description	BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR "THE COMPANY") Incorporation of new indirect wholly-owned subsidiary in Hainan, China
The Board of Directors of Bioalpha Holdings Berhad (“Bioalpha” or “the Company”) wishes to announce that Bioalpha (HK) Limited, the wholly-owned subsidiary of Bioalpha had on 26 August 2020 incorporated a new wholly-owned subsidiary in Hainan, China with the name “Bioalpha (Hainan) Health Biotechnology Limited” under the Foreign Enterprise Law of the People’s Republic of China, Company Law of the People’s Public of China and relevant Chinese laws and regulations with the authorised share capital of Renminbi (“RMB”) 15,000,000 and the intended paid up capital of RMB 15,000,000 only (“the Incorporation”). The principal activities of Bioalpha (Hainan) Health Biotechnology Limited are health food production, import and export; food products trading and selling; pharmaceutical goods production, import and export; production, sales, processing, transportation, storage and other related services of agricultural products. The incorporation of Bioalpha (Hainan) Health Biotechnology Limited does not have any effect on the issued and paid up capital of the Company and the substantial shareholders’ shareholding. The incorporation also does not have any material effect on earnings per share nor net assets per share of Bioalpha and its Group for year ending 31 December 2020. None of the Directors and/or Major Shareholders of the Company and/or persons connected with Directors and/or Major Shareholders has any interest, direct or indirect, in the incorporation of Bioalpha (Hainan) Health Biotechnology Limited. The Board of Directors of the Company is of the opinion that the incorporation of Bioalpha (Hainan) Health Biotechnology Limited is in the best interest of the Bioalpha Group. This announcement is dated 26 August 2020.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2020

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Jun 2020	30 Jun 2019	30 Jun 2020	30 Jun 2019
		$$'000	$$'000	$$'000	$$'000

1	Revenue	6,392	14,033	12,924	26,515
2	Profit/(loss) before tax	-8,199	2,035	-13,503	3,301
3	Profit/(loss) for the period	-8,664	2,028	-14,352	2,972
4	Profit/(loss) attributable to ordinary equity holders of the parent	-7,932	2,034	-13,434	2,892
5	Basic earnings/(loss) per share (Subunit)	-0.87	0.24	-1.51	0.34
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1694		0.1922

icy97

Type	Announcement
Subject	OTHERS
Description	BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR "THE COMPANY") - Collaborative Agreement between Bioalpha International Sdn. Bhd. a wholly-owned subsidiary of Bioalpha and CME Health Sdn Bhd, a wholly-owned subsidiary of CME Group Berhad
INTRODUCTION The Board of Directors of Bioalpha Holdings Berhad (“Bioalpha” or “the Company”) wishes to announce that its wholly-owned subsidiary, Bioalpha International Sdn. Bhd. (“BISB”) had on 17 September 2020 entered into a Collaborative Agreement (“CA”) with CME Health Sdn Bhd (“CME Health”) for BISB to develop, manufacture and supply health food supplement that aims to improve overall immunity and strengthen respiratory systems (“Products”) for CME Health to market exclusively in the South East Asia region. INFORMATION ON CME HEALTH CME Health is incorporated in Malaysia and its intended activities are carrying on buying, selling, distributing and dealing in biological development and pharmaceutical products. It is a wholly-owned subsidiary of CME Group Berhad, a company listed on Main Market of Bursa Malaysia Securities Berhad. SALIENT TERMS OF THE CA Pursuant to the CA, BISB will act as the product development partner and exclusive sole manufacturer of CME Health to produce the Products for a period of 5 years from the date beginning on the CA and CME Health shall maintain the right to extend the CA for a further 5 years subject to mutual agreement from both parties. CME Health will be given the exclusive rights to market, sell, promote and distribute the Products in South East Asia region. The responsibilities of CME Health shall be amongst others, to market and commercialise the Product within South East Asia region as stated by the exclusive rights provided. RATIONALE The CA being incurred is part of the ordinary course of business. INTERESTS OF DIRECTORS AND/OR SUBSTANTIAL SHAREHOLDERS AND/OR PERSON CONNECTED THEM None of the Directors nor major shareholders of Bioalpha, or persons connected with them, has any interest, direct or indirect, in the CA. FINANCIAL EFFECTS The CA will not have any effect on the issued share capital and the substantial shareholders’ shareholdings in Bioalpha as the CA does not involve any issuance of new shares of Bioalpha. It is also not expected to have material effect on the net assets and gearing of Bioalpha Group for the financial year ending 31 December 2020. APPROVAL REQUIRED The CA is not subject to the approval of the shareholders of Bioalpha or any regulatory authorities. STATEMENT BY BOARD OF DIRECTORS The Board of Director of Bioalpha, having taken into consideration all aspects of the CA is of the opinion that the CA is in the best interest of Bioalpha Group. This announcement is dated 18 September 2020.

icy97

Type	Announcement
Subject	NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) FUND RAISING
Description	BIOALPHA HOLDINGS BHD ("BIOALPHA" OR THE "COMPANY")PROPOSED PRIVATE PLACEMENT OF NEW ORDINARY SHARES IN BIOALPHA OF UP TO 5% OF THE ENLARGED NUMBER OF ISSUED SHARES IN BIOALPHA (EXCLUDING ANY TREASURY SHARES) PURSUANT TO SECTIONS 75 AND 76 OF THE COMPANIES ACT 2016 ("PROPOSED PRIVATE PLACEMENT")
On behalf of the Board of Directors of Bioalpha, TA Securities Holdings Berhad wishes to announce that the Company proposes to undertake the Proposed Private Placement. Please refer to the attachment below for further details on the announcement. This announcement is dated 5 November 2020.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3103017

Attachments Bioalpha Holdings Berhad - Proposed Private Placement.pdf

Type	Announcement
Subject	NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) FUND RAISING
Description	BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR THE "COMPANY")PROPOSED PRIVATE PLACEMENT OF NEW ORDINARY SHARES IN BIOALPHA OF UP TO 5% OF THE ENLARGED NUMBER OF ISSUED SHARES IN BIOALPHA (EXCLUDING ANY TREASURY SHARES) PURSUANT TO SECTIONS 75 AND 76 OF THE COMPANIES ACT 2016 ("PROPOSED PRIVATE PLACEMENT")
We refer to the announcements made on 5 November 2020 and 6 November 2020 in relation to the Proposed Private Placement (“Announcements”). Unless otherwise defined, the definitions set out in the Announcements shall apply herein. On behalf of Bioalpha, TA Securities Holdings Berhad wishes to provide additional information in relation to the use of proceeds from the Proposed Private Placement. Further details are set out in the attachment below. This announcement is dated 11 November 2020.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3104132

Attachments Bioalpha Holdings Berhad - Additional Information.pdf

BIOALPHA HOLDINGS BERHAD

1. Details of Corporate Proposal
Involve issuance of new type/class of securities ?	No
Types of corporate proposal	Private Placement
Details of corporate proposal	PRIVATE PLACEMENT OF NEW ORDINARY SHARES IN BIOALPHA HOLDINGS BERHAD ("BIOALPHA") OF UP TO 5% OF THE ENLARGED NUMBER OF ISSUED SHARES IN BIOALPHA (EXCLUDING ANY TREASURY SHARES) PURSUANT TO SECTIONS 75 AND 76 OF THE COMPANIES ACT 2016 ("PRIVATE PLACEMENT")
No. of shares issued under this corporate proposal	52,877,100
Issue price per share ($$)	Malaysian Ringgit (MYR)   0.2500
Par Value($$) (if applicable)
Latest issued share capital after the above corporate proposal in the following
Units	1,110,420,832
Issued Share Capital ($$)	Malaysian Ringgit (MYR) 135,809,745.500
Listing Date	26 Nov 2020

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2020

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2020	30 Sep 2019	30 Sep 2020	30 Sep 2019
		$$'000	$$'000	$$'000	$$'000

1	Revenue	6,871	17,276	19,795	43,791
2	Profit/(loss) before tax	-10,441	3,516	-23,946	6,816
3	Profit/(loss) for the period	-10,441	3,164	-24,795	6,135
4	Profit/(loss) attributable to ordinary equity holders of the parent	-9,709	3,105	-23,908	5,996
5	Basic earnings/(loss) per share (Subunit)	-0.94	0.36	-2.42	0.70
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1573		0.1922

Type	Announcement
Subject	OTHERS
Description	BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR "THE COMPANY") - Collaborative Agreement between Bioalpha International Sdn. Bhd. a wholly-owned subsidiary of Bioalpha and Ritamix Global Limited
INTRODUCTION The Board of Directors of Bioalpha Holdings Berhad (“Bioalpha” or “the Company”) wishes to announce that its wholly-owned subsidiary, Bioalpha International Sdn. Bhd. (“BISB”) had on 2 December 2020 entered into a Collaborative Agreement (“CA”) with Ritamix Global Limited (“Ritamix”) for BISB to manufacture and supply health supplement products for Ritamix to market in China (including Hong Kong) and South East Asia. INFORMATION ON RITAMIX Ritamix Global Ltd is a company listed on the main market of Hong Kong Stock Exchange (“HKEX”) with more than 37 years of track record, principally engaging in (i) distribution of animal feed additives and, to a lesser extent, human food ingredients; and (ii) manufacturing of animal feed additives premixes. The Company sourced over 300 brand products from over 70 suppliers of different brand names to promote and distribute their products in Malaysia. They also produced over 150 own brand animal feed additives premixes for sales in Malaysia and overseas. SALIENT TERMS OF THE CA Pursuant to the CA, BISB will act as the contract manufacturer for Ritamix in the development of health supplement products not limited to immunity and longevity products. The products are formulated and owned by Ritamix. Ritamix shall market and distribute the products in China (including Hong Kong) and South East Asia. RATIONALE The CA being incurred is part of the ordinary course of business. INTERESTS OF DIRECTORS AND/OR SUBSTANTIAL SHAREHOLDERS AND/OR PERSON CONNECTED THEM None of the Directors nor major shareholders of Bioalpha, or persons connected with them, has any interest, direct or indirect, in the CA. FINANCIAL EFFECTS The CA will not have any effect on the issued share capital and the substantial shareholders’ shareholdings in Bioalpha as the CA does not involve any issuance of new shares of Bioalpha. It is also not expected to have material effect on the net assets and gearing of Bioalpha Group for the financial year ending 31 December 2020. APPROVAL REQUIRED The CA is not subject to the approval of the shareholders of Bioalpha or any regulatory authorities. STATEMENT BY BOARD OF DIRECTORS The Board of Director of Bioalpha, having taken into consideration all aspects of the CA is of the opinion that the CA is in the best interest of Bioalpha Group. This announcement is dated 2 December 2020.

Type	Reply to Query
Reply to Bursa Malaysia's Query Letter - Reference ID	IQL-04122020-00002
Subject	COLLABORATIVE AGREEMENT BETWEEN BIOALPHA INTERNATONAL SDN BHD, A WHOLLY OWNED SUBSIDIARY OF BIOALPHA HOLDINGS BERHAD AND RITAMIX GROUP LIMITED ("COLLABORATIVE AGREEMENT")
Description	BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR "THE COMPANY") - Additional Information on the Collaborative Agreement between Bioalpha International Sdn. Bhd. a wholly-owned subsidiary of Bioalpha and Ritamix Global Limited
Query Letter Contents	We refer to your Company’s announcement dated 2 December 2020, in respect of the aforesaid matter. In this connection, kindly furnish Bursa Securities with the following additional information for public release:- 1.     The commencement and expiry dates of the Collaborative Agreement and whether the Collaborative Agreements is subject to renewal, and if yes, the details of such renewal. 2.     The risks in relation to the Collaboration Agreement. 3.     The financial effect of the Collaborative Agreement on the earning per share of the Group.
Unless otherwise stated, all abbreviations used herein shall have the same meaning as those mentioned in the announcement dated 2 December 2020 in relation to the Collaborative Agreement (“Announcement”). The Board of Directors of Bioalpha Holdings Berhad (“Bioalpha” or “the Company”) wishes to inform that the Company has received Bursa Malaysia Securities Berhad’s request dated 4 December 2020 for additional information in relation to the Company’s announcement made on 2 December 2020. The additional information are as follows: 1.           The commencement and expiry dates of the Collaborative Agreement and whether the Collaborative Agreement is subject to renewal, and if yes, the details of such renewal. The Collaborative Agreement (“CA”) has commenced on 2 December 2020 for the initial contract period of 5 years (“Initial Contract Period”). The CA may be extended for a further period of 5 years to be mutually agreed by both Parties. 2.           The risks in relation to the Collaboration Agreement. Bioalpha does not expect any material risk arising from the CA other than the normal operational risk associated with the CA, which Bioalpha would take appropriate measures to mitigate. 3.           The financial effect of the Collaborative Agreement on the earning per share of the Group. Barring any unforeseen circumstances, the Board envisages the CA to contribute positively to the earnings per share of Bioalpha in the future. This announcement is dated 4 December 2020.

Type	Announcement
Subject	MULTIPLE PROPOSALS
Description	BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR THE "COMPANY")(I)        PROPOSED RIGHTS ISSUE OF SHARES; (II)        PROPOSED RIGHTS ISSUE OF ICPS;(III)        PROPOSED PLACEMENT OF ICPS;(IV)        PROPOSED CONSTITUTION AMENDMENTS; AND(V)        PROPOSED DEED POLL AMENDMENTS(COLLECTIVELY, THE "PROPOSALS")
On behalf of the Board of Directors of Bioalpha (“Board”), TA Securities Holdings Berhad (“TA Securities”) wishes to announce that the Company proposes to undertake the Proposals. Please refer to the attachment below for further details on the announcement. This announcement is dated 19 January 2021.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3122365

Attachments Bioalpha Holdings Berhad - Announcement of the Proposals - 19 January 2021.pdf

Type	Announcement
Subject	MEMORANDUM OF UNDERSTANDING
Description	BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR "THE COMPANY")MEMORANDUM OF UNDERSTANDING ("MOU") BETWEEN BIOALPHA INTERNATIONAL SDN BHD AND iHEAL MEDICAL SERVICES SDN BHD
The Board of Directors of Bioalpha wishes to announce that Bioalpha International Sdn Bhd (“BISB”), a wholly-owned subsidiary of Bioalpha, had on 25 January 2021 entered into a Memorandum of Understanding (“MOU”) with iHEAL Medical Services Sdn Bhd (“iHEAL”), which outlines the intention of both parties to work in collaboration to provide Covid-19 vaccination services to the public. Kindly refer to the attached file for further information. This announcement is dated 25 January 2021.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3123823

Attachments Bioalpha_MOU with iHEAL (for bursa release).pdf

Type	Announcement
Subject	OTHERS
Description	BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR "THE COMPANY")  -  PROCUREMENT AND DISTRIBUTION AGREEMENT FOR VACCINES INCLUDING COVID-19 VACCINE
The Board of Directors of Bioalpha Holdings Berhad (“Bioalpha” or “the Company”) wishes to announce that Bioalpha International Sdn. Bhd. (“BISB”), a wholly-owned subsidiary of Bioalpha has on 25 January 2021 entered into a Procurement and Distribution Agreement (“Agreement”) with Shanghai Bukun Trading Co., Ltd (“SBTC”), a wholly-owned subsidiary of Sinopharm (Hainan) Health Industry Co., Ltd (“Sinopharm Hainan”) for the procurement and distribution of vaccines in Malaysia, including but not limited to the Covid-19 vaccine developed by Sinovac Biotech Co., Ltd. (“Sinovac Biotech”), subject to relevant authorities’ approvals which include the National Pharmaceutical Regulatory Agency (“NPRA”). This arrangement has also been endorsed by Sinovac Biotech with regards to the Covid-19 vaccine. Kindly refer to the attached file for further information. This announcement is dated 25 January 2021.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3123824

Attachments Bioalpha_Announcement_Sinovac (for bursa release).pdf

Type	Announcement
Subject	MEMORANDUM OF UNDERSTANDING
Description	BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR "THE COMPANY")MEMORANDUM OF UNDERSTANDING ("MOU") BETWEEN BIOALPHA INTERNATIONAL SDN BHD AND ZUELLIG PHARMA SDN BHD
The Board of Directors of Bioalpha wishes to announce that Bioalpha International Sdn Bhd (“BISB”), a wholly-owned subsidiary of Bioalpha, had on 22 January 2021 entered into a Memorandum of Understanding (“MOU”) with Zuellig Pharma Sdn Bhd (“ZP”) to facilitate the importation, warehousing and distribution of the Covid-19 vaccine in Malaysia. Kindly refer to the attached file for further information. This announcement is dated 25 January 2021.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3123825

Attachments Bioalpha_MOU with Zuellig Pharma_for Bursa release.pdf

icy97

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR "THE COMPANY")ACQUISITION OF A COMPANY NAMELY, GUIZHOU HONGBO SUPPLY CHAIN CO. LTD FOR CASH CONSIDERATION OF RMB20,000.00 EQUIVALENT TO RM12,851.00 BY ITS INDIRECT WHOLLY-OWNED SUBSIDIARY, BIOALPHA (HAINAN) HEALTH CO. LTD.
1.      INTRODUCTION This is a voluntary announcement pursuant to Rule 10.05(2) of the Ace Market Listing Requirements of Bursa Malaysia Securities Berhad, the Board of Directors of Bioalpha Holdings Berhad (“Bioalpha” or “the Company”) wishes to announce that its indirect wholly-owned subsidiary, Bioalpha (Hainan) Health Co. Ltd. (“BHBL”) had on 20 October 2021 completed the acquisition of  a company namely Guizhou Hongbo Supply Chain Co. Ltd. (“Guizhou Hongbo”) for a total cash purchase consideration of RMB20,000.00 equivalent to RM12,851.00. (“Acquisition”). Following the Acquisition, Guizhou Hongbo will become a 100% owned subsidiary of BHBL and indirect 100% wholly owned subsidiary of Bioalpha. 2.      INFORMATION ON GUIZHOU HONGBO Guizhou Hongbo was incorporated on 31 March 2021 at 7th floor, Liu Gang building, Xiangyang Road, Zhazuo Street, Xiuwen District, Guiyang City, Guizhou Province, China. Their business operations included supply chain management services that involved food processing and productions, food management, general tradings which includes import and  exports, agricultural related services and warehousing. The Director and the shareholder of  Guizhou Hongbo is Mr Yao Hong. The registered capital of Guizhou Hongbo is RMB2,000,000. 3.      SOURCE OF FUNDING The Acquisition will be funded via the Company’s internally generated funds. 4.      LIABILITIES TO BE ASSUMED Save for the liabilities in the financial statements of Guizhou Hongbo, which will be consolidated into the results of the Company’s Group of Companies, there are no other liabilities including contingent liabilities and guarantees, to be assumed by the Company arising from the Acquisition. 5.      RATIONALE OF THE ACQUISITION The Acquisition will provide to Bioalpha Group opportunity to participate in health food and ingredients supply and to facilitate trading activities in Guizhou province. 6.      APPROVAL REQUIRED The Acquisition is not subject to the approval from the shareholders of Bioalpha or any other relevant regulatory authorities and/or parties. 7.      INTEREST OF DIRECTORS, MAJOR SHAREHOLDERS AND/OR PERSON CONNECTED TO THEM None of the Directors and/or Major Shareholders of Bioalpha and/or persons connected to them have any interest, direct or indirect, in the Acquisition. 8.         FINANCIAL EFFECTS 8.1       Share capital and substantial shareholders’ shareholdings The Acquisition will not have any effect on the issued and paid-up share capital of Bioalpha and the shareholding of its substantial shareholders as the Acquisition does not entail any issuance of new ordinary shares in the Company and/or convertible securities in the Company. 8.2       Net assets and gearing         The Acquisition will not have any immediate material effect on the net assets of Bioalpha Group for the financial year ending 31 December 2021. 8.3       Earnings per share (“EPS”) The Acquisition is not expected to have a material effect on the consolidated earnings and EPS of Bioalpha Group. 9.         DIRECTORS’ RECOMMENDATION The Board, having considered all aspects of the Acquisition, including the rationale and benefits of the Acquisition, is of the opinion that the Acquisition is in the best interest of the Bioalpha Group. 10.       HIGHEST PERCENTAGE RATIO APPLICABLE TO THE    ACQUISITION The highest percentage ratio applicable to the Acquisition pursuant to Rule 10.02(g) of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad is 0.01% based on the audited consolidated financial statements of Bioalpha for the financial year ended 31 December 2020. 11.       DOCUMENT FOR INSPECTION The SSA is available for inspection at the registered office of the Company at Level 5, Block B, Dataran PHB, Saujana Resort, Section U2, 40150 Shah Alam,  Selangor, during normal working hours from Monday to Friday (except Saturday, Sunday and Public Holidays) for a period of three (3) months from the date of this announcement. This announcement is dated 20 October 2021.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2021

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2021	30 Sep 2020	30 Sep 2021	30 Sep 2020
		$$'000	$$'000	$$'000	$$'000

1	Revenue	28,368	6,871	82,895	19,795
2	Profit/(loss) before tax	1,833	-10,441	4,965	-23,946
3	Profit/(loss) for the period	1,499	-10,441	4,445	-24,795
4	Profit/(loss) attributable to ordinary equity holders of the parent	1,573	-9,709	4,561	-23,908
5	Basic earnings/(loss) per share (Subunit)	0.13	-0.94	0.40	-2.42
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1593		0.1641